Because of the risk of hepatotoxicity, Juxtapid is available only through a restricted program called the JUXTAPID REMS Program. Aegerion Pharmaceuticals has worked with the US Food & Drug Administration (FDA) to develop this Risk Evaluation and Mitigation Strategy (REMS) Program to:
Educate prescribers about:
- the risk of hepatotoxicity associated with the use of Juxtapid; and
- the need to monitor patients during treatment with Juxtapid as per product labeling.
Restrict access to therapy with Juxtapid to patients with a clinical or laboratory diagnosis consistent with HoFH.
Monday-Friday: 8 AM-7 PM ET
To learn more about the risk of hepatotoxicity associated with the use of Juxtapid, please refer to the Prescribing Information.